The 2nd Bacteriophage Therapy Summit returns once again to bring together industry, leading academics, regulatory bodies and technology experts to accelerate the clinical development, regulation and approval of bacteriophage products.

As we enter the post-antibiotic era, the re-emergence of phage therapy acts as a potential viable replacement for antibiotics. However, the re-emergence does not come without challenges; large scale production, showing efficacy in the clinical setting and navigating a developing regulatory field are just a few limitations the field is currently facing.
This is your opportunity to join leaders developing the next generation of phage therapy products to discuss the latest case-studies and forge collaborations to unlock the full potential of bacteriophage therapeutics.